Patent 11415571 was granted and assigned to Tempus Labs (company) on August, 2022 by the United States Patent and Trademark Office.
Methods, systems, and software are provided for using organoid cultures, e.g., patient-derived tumor organoid cultures, to improve treatment predictions and outcomes.